Cargando…

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line

Seasonal influenza infections have a significant global impact leading to increased health and economic burden. The efficacy of currently available seasonal influenza vaccines targeting polymorphic surface antigens has historically been suboptimal. Cellular immune responses against highly conserved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Folegatti, Pedro M., Bellamy, Duncan, Flaxman, Amy, Mair, Catherine, Ellis, Chris, L. Ramon, Raquel, Ramos Lopez, Fernando, Mitton, Celia, Baker, Megan, Poulton, Ian, Lawrie, Alison, Roberts, Rachel, Minassian, Angela, Ewer, Katie J., Evans, Thomas G., Hill, Adrian V. S., Gilbert, Sarah C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466103/ https://www.ncbi.nlm.nih.gov/pubmed/30909516 http://dx.doi.org/10.3390/vaccines7010033

Ejemplares similares

The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis
por: Lohr, Verena, et al.
Publicado: (2014)

Potent CD8(+) T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1
por: Berthoud, Tamara K., et al.
Publicado: (2011)

Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells
por: Lohr, Verena, et al.
Publicado: (2012)

Development of an efficient veterinary rabies vaccine production process in the avian suspension cell line AGE1.CR.pIX
por: Trabelsi, Khaled, et al.
Publicado: (2022)

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
por: Folegatti, Pedro M., et al.
Publicado: (2021)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
por: Folegatti, Pedro M., et al.
Publicado: (2019)

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
por: Butler, Chris, et al.
Publicado: (2021)

Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1
por: Lambe, Teresa, et al.
Publicado: (2013)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, Ansar A., et al.
Publicado: (2012)

A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years
por: Antrobus, Richard D., et al.
Publicado: (2012)

Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice
por: Langenmayer, Martin C., et al.
Publicado: (2023)

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
por: Folegatti, Pedro M, et al.
Publicado: (2020)

Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza
por: Lynch, Garry W, et al.
Publicado: (2009)

Adaptive Heterosubtypic Immunity to Low Pathogenic Avian Influenza Viruses in Experimentally Infected Mallards
por: Segovia, Karen M., et al.
Publicado: (2017)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
por: de Graaf, Hans, et al.
Publicado: (2021)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
por: Minassian, Angela M, et al.
Publicado: (2011)

A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS
por: de Barra, Eoghan, et al.
Publicado: (2014)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
por: Afolabi, Muhammed O, et al.
Publicado: (2016)

Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
por: Bowyer, Georgina, et al.
Publicado: (2014)

Highly Pathogenic Avian Influenza Virus Infection of Mallards with Homo- and Heterosubtypic Immunity Induced by Low Pathogenic Avian Influenza Viruses
por: Fereidouni, Sasan R., et al.
Publicado: (2009)

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors
por: Sheehy, Susanne H., et al.
Publicado: (2012)

Heterosubtypic Protections against Human-Infecting Avian Influenza Viruses Correlate to Biased Cross-T-Cell Responses
por: Zhao, Min, et al.
Publicado: (2018)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial
por: Rowland, Rosalind, et al.
Publicado: (2013)

A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol
por: Swayze, Hannah, et al.
Publicado: (2019)

Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans
por: Lillie, Patrick J., et al.
Publicado: (2012)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
por: Sharpe, Hannah R., et al.
Publicado: (2022)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA Antigens
por: Laddy, Dominick J., et al.
Publicado: (2008)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
por: Mensah, Victorine A., et al.
Publicado: (2016)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
por: Brookes, Roger H., et al.
Publicado: (2008)

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
por: Alharbi, Naif Khalaf, et al.
Publicado: (2022)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Homo- and Heterosubtypic Low Pathogenic Avian Influenza Exposure on H5N1 Highly Pathogenic Avian Influenza Virus Infection in Wood Ducks (Aix sponsa)
por: Costa, Taiana P., et al.
Publicado: (2011)

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley Fever in adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
por: Jenkin, Daniel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_flbc6mfo9qlp0c8so8t09but36